SynthesisCommunications biology2022
A comprehensive transcriptomic comparison of hepatocyte model systems improves selection of models for experimental use.
Synthesis in Communications biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Systems biology framework for the rational design of operational conditions for in vitro/in vivo translation of tissue models.Science advances · 2026Article
- An Immunocompetent Hepatic Organoid Model Reveals Conserved Hepatic Immune Dysregulation DuringInternational journal of molecular sciences · 2026Article
- A DPHV-liver module recapitulates AML infiltration and chemotherapy-induced hepatotoxicity with translational utility.Science advances · 2026Article
- Generation of proliferative hESC-derived grape-clustered hepatocyte organoids with multipolar architecture as regenerative counterpart via synergy of YAP and IGF2 pathways.Cell death & disease · 2026Article
- Article
- Organoids for Metabolic Disease Modeling.Journal of inherited metabolic disease · 2026Review
- Evaluation of the Immortalized Primary Human Hepatocyte Cell Line Fa2N-4 as a Model for Metabolic Dysfunction-Associated Steatotic Liver Disease.Gastro hep advances · 2026Article
- Tissue-resident macrophage and dendritic cells drive type I IFN immunity to enteroviruses in the liver.PLoS pathogens · 2026Article
- KANSL3 directs transcriptional programs essential for hepatic metabolism and differentiation.Life science alliance · 2025Article
- Primary Human Tissue Models for Metabolic Dysfunction-Associated Liver Disease - toward Streamlining Drug Discovery with Patient-Derived Assays.Advanced biology · 2025Review
- Elimination of CDX2 restricts intestinal hybrid differentiation signatures in stem cell-derived hepatocyte-like cells.Stem cell research & therapy · 2025Article
- Article
- The Potential Hepatocyte Differentiation Targets and MSC Proliferation by FH1.Journal of cellular and molecular medicine · 2025Article
- Hepatocytes derived from human induced pluripotent stem cells: Towards establishing anCurrent research in toxicology · 2025Article
- Tracking hemopexin intracellularly and defining hemopexin protein "interactomes" in human immune and liver cell models.Frontiers in physiology · 2025Article
- Development of a CYP2D6-enhanced HepaRG cell model with improved CYP2D6 metabolic capacity.PloS one · 2025Article
- Comparative analysis of small molecule and growth factor-derived human induced pluripotent stem cell-derived hepatocyte-like cells.Frontiers in cell and developmental biology · 2025Article
- DNA Methylation in the CYP3A Distal Regulatory Region (DRR) Is Associated with the Expression of CYP3A5 and CYP3A7 in Human Liver Samples.Molecules (Basel, Switzerland) · 2024Article
- Article
- Time-course characterization of whole-transcriptome dynamics of HepG2/C3A spheroids and its toxicological implications.Toxicology letters · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The myriad of available hepatocyte in vitro models provides researchers the possibility to select hepatocyte-like cells (HLCs) for specific research goals. However, direct comparison of hepatocyte models is currently challenging. We systematically searched the literature and compared different HLCs, but reported functions were limited to a small subset of hepatic functions. To enable a more comprehensive comparison, we developed an algorithm to compare transcriptomic data across studies that tested HLCs derived from hepatocytes, biliary cells, fibroblasts, and pluripotent stem cells, alongside primary human hepatocytes (PHHs). This revealed that no HLC covered the complete hepatic transcriptome, highlighting the importance of HLC selection. HLCs derived from hepatocytes had the highest transcriptional resemblance to PHHs regardless of the protocol, whereas the quality of fibroblasts and PSC derived HLCs varied depending on the protocol used. Finally, we developed and validated a web application (HLCompR) enabling comparison for specific pathways and addition of new HLCs. In conclusion, our comprehensive transcriptomic comparison of HLCs allows selection of HLCs for specific research questions and can guide improvements in culturing conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.